Mesalazine

Drug Profile

Mesalazine

Alternative Names: Asacol; Asacolon; Fivasa; Lixacol; Octasa; TP 05; Z-206

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tillotts Pharma
  • Developer Kyowa Hakko Kirin; Lek Pharmaceuticals d.d.; Tillotts Pharma; Zeria
  • Class Aminosalicylic acids; Anti-inflammatories; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Crohn's disease; Inflammatory bowel diseases; Proctitis; Ulcerative colitis
  • Phase II Irritable bowel syndrome

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Ulcerative-colitis in Switzerland (PO, Tablet)
  • 16 Jun 2017 Registered for Ulcerative colitis in Japan (PO, controlled release, od) (Zeria pipeline, June 2017)
  • 01 Feb 2017 Tillotts Pharma completes a phase II trial in Irritable bowel syndrome in Sweden (PO) (NCT01699438)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top